Trial Information
Determination of Optimal Dose and Safety Profile of Optison Ultrasound Contrast Agent in Pediatric Solid Tumor Patients
Inclusion Criteria:
- Age: 2-20 years old
- Subject has a known or suspected solid soft tissue tumor in the abdomen or pelvis.
- Subject is scheduled for other imaging or is already scheduled for an ultrasound or
has already had adequate imaging performed at an outside institution.
- Subject is able to lie still for the exam without sedation.
Exclusion Criteria:
- Known or suspected hypersensitivity to albumin, blood or blood products.
- History of open heart surgery, cyanotic congenital heart disease or an axygen
saturation of less than 96% as determined by pulse oximetry.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
To learn the best dose of Optison™ ultrasound contrast agent that can be safely given to children with abdominal or pelvic tumors.
Outcome Time Frame:
Unknown-study temporarily closed.
Safety Issue:
Yes
Principal Investigator
Mary E. McCarville, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
St. Jude Children's Research Hospital
Authority:
United States: Food and Drug Administration
Study ID:
OPTUS
NCT ID:
NCT00186953
Start Date:
June 2002
Completion Date:
August 2004
Related Keywords:
- Abdominal Neoplasms
- Pelvic Neoplasms
- Ultrasound
- Abdominal tumors
- Pelvic tumors
- Abdominal Neoplasms
- Neoplasms
- Pelvic Neoplasms
Name | Location |
St. Jude Children's Research Hospital |
Memphis, Tennessee 38105-2794 |